Barbaro Memorial Fund Backs Laminitis Research

The NTRA Charities recently granted over $90,000 out in support of research into laminitis.

The National Thoroughbred Racing Association’s subsidiary, NTRA Charities, recently handed out $90,801 in support of laminitis research.

The money was distributed from the NTRA Charities Barbaro Memorial Fund, established in memory of 2006 Kentucky Derby winner Barbaro, who succumbed to laminitis in 2007.

One new and two continuing research projects will be funded. The new study, “Effect of Digital Hypothermia on Inflammatory Injury in Laminitis,” by James Belknap, DVM, Ph.D., of Ohio State University’s College of Veterinary Medicine, is a two-year project funded for $82,109.

The continuing projects, which will collectively receive $8,692, are “Targeting 5-HT in Equine Laminitis,” by Douglas Allen, DVM, at the University of Georgia’s College of Veterinary Medicine, and “Treatment of Equine Laminitis with Doxycycline,” by Susan Eades, DVM, Ph.D., at the Louisiana State University’s School of Veterinary Medicine.

Both continuing studies, which originally were funded with $100,000 from the Barbaro fund to the Grayson-Jockey Club Research Foundation in 2007, are on schedule to complete research papers for peer-reviewed scientific journals.

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.